Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Junji Tsurutani
Showa University - Advanced Cancer Translational Research Institute
Japan
Learn more about SSRN Profiles
SCHOLARLY PAPERS
2
DOWNLOADS
253
TOTAL CITATIONS
0
Feedback
Scholarly Papers (2)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
CYP2D6
Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study
Number of pages: 35
Posted: 06 Apr 2019
Kenji Tamura
,
Chiyo K. Imamura
,
Toshimi Takano
,
Shigehira Saji
,
Takeharu Yamanaka
,
Kan Yonemori
,
Masato Takahashi
, Junji Tsurutani,
Reiki Nishimura
,
Kazuhiko Sato
,
Akira Kitani
,
Naoto T. Ueno
,
Taisei Mushiroda
,
Michiaki Kubo
,
Yasuhiro Fujiwara
and
Yusuke Tanigawara
National Cancer Center Hospital - Department of Breast and Medical Oncology, Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics, Toranomon Hospital - Department of Medical Oncology, Fukushima Medical University, Yokohama City University, National Cancer Center Hospital - Department of Breast and Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Showa University - Advanced Cancer Translational Research Institute, Kumamoto Shinto General Hospital, Tokyo-West Tokushukai Hospital, Seirei Sakura Citizen Hospital, University of Texas at Houston - MD Anderson Cancer Center, RIKEN Center for Integrative Medical Sciences, RIKEN Center for Integrative Medical Sciences, National Cancer Center Hospital - Department of Breast and Medical Oncology and Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics
Downloads
147
(502,974)
View PDF
Download
Abstract:
breast cancer, CYP2D6, endoxifen, genotype-guided dosing, tamoxifen
2.
Phase 2 Study of Nivolumab Plus Bevacizumab Plus Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer
Number of pages: 34
Posted: 04 May 2021
Yukinori Ozaki
, Junji Tsurutani,
Toru Mukohara
,
Tsutomu Iwasa
,
Masato Takahashi
,
Yuko Tanabe
,
Hidetaka Kawabata
,
Norikazu Masuda
,
Manabu Futamura
,
Hironobu Minami
,
Koji Matsumoto
,
Kenichi Yoshimura
,
Shigehisa Kitano
and
Toshimi Takano
Toranomon Hospital - Department of Medical Oncology, Showa University - Advanced Cancer Translational Research Institute, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, Hyogo Cancer Center - Department of Medical Oncology, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads
106
(659,652)
View PDF
Download
Abstract:
Feedback